Company Overview
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
Why Investors Should Care
Revenue has grown at a 40.3% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.17.
Recent Developments
- Dec 2025 Revenue of $89.06M (+36.1% YoY); net profit $-53.41M.
- Trailing 12 Months Year-on-year growth — revenue +32.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 40.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 40.33% |
| 1 Year: | 32.50% |
Stock Price Performance
| 1 Year: | +127.79% |
| 6 Months: | +28.09% |
| 3 Months: | +49.64% |
| 1 Month: | +13.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 40.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CBLL CeriBell, Inc. R2KR3KPHARMA | 27.13 | -15.41 | $1.04B | 0.00% | -33.07% | -43.93% | 40.33% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 11.61M | 14.40M | 15.31M | 17.20M | 20.49M | 21.20M | 22.59M | 26.49M | 28.10M |
| Gross Profit | - | - | 9.73M | 12.34M | 13.16M | 15.01M | 18.01M | 18.68M | 19.94M | 23.12M | 25.94M |
| Operating Income | - | - | -7.16M | -8.45M | -8.44M | -9.94M | -14.21M | -14.95M | -14.65M | -20.75M | -19.98M |
| Net Income | -7.92M | -6.22M | -7.05M | -8.52M | -8.94M | -10.42M | -12.78M | -13.64M | -13.46M | -19.74M | -19.27M |
| Diluted EPS | - | - | -1.32 | -1.56 | -1.61 | -1.85 | -0.36 | -0.38 | -0.37 | -0.52 | -0.51 |
| R&D Expense | - | - | 2.31M | 2.98M | 3.27M | 3.40M | 4.25M | 4.85M | 4.98M | 6.16M | 6.75M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 45.23M | 65.44M | 89.06M |
| Gross Profit | 38.16M | 56.75M | 78.27M |
| Operating Income | -30.04M | -39.71M | -58.40M |
| Net Income | -29.46M | -40.45M | -53.41M |
| Diluted EPS | -5.56 | -3.39 | -1.46 |
| R&D Expense | 8.99M | 13.56M | 19.14M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 58.92M | 225.41M | 195.80M |
| Total Equity | -86.40M | -112.25M | 191.16M | 155.34M |
| Cash & Equivalents | - | 34.49M | 194.37M | 40.48M |
| Total Liabilities | - | 23.76M | 34.25M | 40.47M |
| Current Liabilities | - | 21.60M | 12.99M | 19.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -29.16M | -35.04M | -40.81M |
| Investing Cash Flow | -1.76M | -1.60M | -118.14M |
| Financing Cash Flow | -2.82M | 196.52M | 5.05M |
| Capital Expenditure | -983.00K | -1.34M | -767.00K |
| Free Cash Flow | -30.14M | -36.38M | -41.58M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 84.4% | 86.7% | 87.9% |
| Operating Margin % | -66.4% | -60.7% | -65.6% |
| Net Margin % | -65.1% | -61.8% | -60.0% |
| ROE % | 26.2% | -21.2% | -34.4% |
| ROCE % | -80.5% | -18.7% | -33.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.83% | 5.69M | $134.49M |
| 2 | TPG GP A, LLC | 9.80% | 3.76M | $88.88M |
| 3 | Red Tree Management, LLC | 5.75% | 2.21M | $52.12M |
| 4 | Blackrock Inc. | 5.04% | 1.94M | $45.75M |
| 5 | Vanguard Capital Management LLC | 2.95% | 1.13M | $26.71M |
| 6 | KCM Capital Inc | 2.93% | 1.12M | $26.58M |
| 7 | Federated Hermes, Inc. | 2.45% | 939.60K | $22.20M |
| 8 | Franklin Resources, Inc. | 2.39% | 918.35K | $21.70M |
| 9 | Adage Capital Partners GP L.L.C. | 2.35% | 900.00K | $21.27M |
| 10 | Bank Of New York Mellon Corporation | 2.34% | 896.49K | $21.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CBLL
CeriBell, Inc. (CBLL) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE80SktvcjhxY2F5cUJrR2dMT1VLM3ZxaHFjUXhVLWFBano5VWtLQVpuYTFabXgxTVRlQk9SYXNfWTlIOFZBUzdsOVJIeVpuNmI0TGc?oc=5" target="_blank">CeriBell, Inc. (CBLL) Stock Price, News, Quote & History…
CeriBell (CBLL) Stock Premium Rides High Margins Despite Deeper Losses - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNNkVXc0c2ZnZ3ZXdzOVA2N1Jaa204X0YyUUt6cjZfamRiTkROWlM5OUEwWU9lNWw4N09zdDU4Ri0zQ3lQdjVCYzVuTmt2ZGk0MmVVZ0NsZnZ1Q2U5ZENINDl6M1ZrWUlockRXQkpLTkY0MjlybXJvQ2h4QzFQSlRSb2xwbUR5cWJOS0U2cE…
Is CeriBell, Inc. (CBLL) Among the Best Brain-Computer Interface Stocks to Buy? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQOGNpX25NUGN0SDE1dXhjMTlHN3BoekllRDdDSEhZMG9hYnM5SmY5dl9zd1l1ell3TXZqbUNGZU5vU1NDT1VKdHZQX0pyYjRwTTFiX2RGUEtNS29seEZjLXRGMjZYTUxtb3NDRjJlTGZIVGF4ZkNsc25vUWoyU2c2Wm9QbklySG9pTVQ1cU…
Insider Sale: Chief Financial Officer of $CBLL Sells 33,512 Shares | CBLL Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNemNBd3ptNmhVS05vY3dLcmRoVEdRdWpDQU10VmloajA1dURGVmx0X3JaVXhFSjlKemhoSG1hcFBSM3NyN3h1VXVwNVNrVHhfVE5NakxOUllnZ1BJV3REajRuRUdhTnBXSWk2WmVCZmRYQUNNVExnUTZSM1oyaFd2cV9wVXQ5aWpJQV9jMm…
Option exercises accompany a 4,887-share sale at $24.38 by Ceribell (CBLL) CTO Raymond Woo. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQVFZ3SENNRTRDbm54VEtXeW54cm0tYWtyM0U5c0ZJTTFaMGlLb0o0QzBNaDBQakFUa1Y2dmpJY0dkWmtJMURWZjBVenFHSjNFRTBLM3VVcml3Z29JY1FucEtPZlR4SWdyMnk1emFrcFhaT1U4TkFGOTR4UVpia1BhS3Z3WnlQdWY1bUVmYk…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBGQ2MyS2p6VU5xbjhxN3poaTlzcUF1a052UjctN09lcUxHWHROZmUxVThXYVRmS1Z3dVVxZUY0QWd5TjFvX015ZHZUanBFQUZ2?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
CBLL — Frequently Asked Questions
What is the current share price of CeriBell, Inc. (CBLL)?
As of 2026-10-23 16:27 PDT, CeriBell, Inc. (CBLL) trades at $27.13 on NasdaqGS. Its 52-week range is $10.92 to $27.68.
What is the market capitalisation of CBLL?
CeriBell, Inc. (CBLL) has a market capitalisation of $1.04B on NasdaqGS.
What is the P/E ratio of CBLL?
CBLL trades at a trailing price-to-earnings (P/E) ratio of -15.41. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 7.04.
What is the return on equity (ROE) of CBLL?
CBLL has a return on equity (ROE) of -43.93%. Its return on capital employed (ROCE) is -33.07%.
Is CBLL a good stock to buy?
This page provides a data-driven analysis of CeriBell, Inc. (CBLL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.